Epidemiology

You have full text access to this OnlineOpen article

IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

  1. Jocelyn M. Weiss1,†,*,
  2. Wen-Yi Huang1,
  3. Sabina Rinaldi2,
  4. Thomas R. Fears1,
  5. Nilanjan Chatterjee1,
  6. David Chia3,
  7. E. David Crawford4,
  8. Rudolf Kaaks2,
  9. Richard B. Hayes1

Article first published online: 27 JUN 2007

DOI: 10.1002/ijc.22921

Issue

International Journal of Cancer

International Journal of Cancer

Volume 121, Issue 10, pages 2267–2273, 15 November 2007

Additional Information

How to Cite

Weiss, J. M., Huang, W.-Y., Rinaldi, S., Fears, T. R., Chatterjee, N., Chia, D., Crawford, E. D., Kaaks, R. and Hayes, R. B. (2007), IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int. J. Cancer, 121: 2267–2273. doi: 10.1002/ijc.22921

Author Information

  1. 1

    Division of Cancer Epidemiology and Genetics, NCI/NIH, Bethesda, MD

  2. 2

    International Agency for Research on Cancer, Lyon, France

  3. 3

    UCLA Immunogenetics Center, Los Angeles, CA

  4. 4

    University of Colorado Health Sciences Center, Denver, CO

  1. †

    Fax: +301-402-1819.

*Division of Cancer Epidemiology and Genetics, NCI, Occupational and Environmental Epidemiology Branch, 6120 Executive Boulevard, EPS 8123, MSC 7240, Bethesda, MD 20892, USA

Publication History

  1. Issue published online: 25 SEP 2007
  2. Article first published online: 27 JUN 2007
  3. Manuscript Accepted: 9 MAY 2007
  4. Manuscript Received: 16 MAR 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (91K)

Keywords:

  • prostate;
  • cancer;
  • insulin-like growth factors

Abstract

IGF-1 and IGFBP-3 may influence risk of prostate cancer through their roles in cellular growth, metabolism and apoptosis, however, epidemiologic results have been inconsistent. The role of obesity in prostate cancer risk is not clearly understood, but hyperinsulinemia-related increases in bioactive IGF-1 levels, associated with obesity, could be a component of the relationship between the IGF-axis and prostate cancer. We conducted a nested case–control study in the prospective Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial to examine associations between IGF-1 and IGFBP-3 and risk of prostate cancer. A total of 727 incident prostate cancer cases and 887 matched controls were selected for this analysis. There was no clear overall association between IGF-1, IGFBP-3 and IGF-1:IGFBP-3 molar ratio (IGFmr) and prostate cancer risk, however, IGFmr was associated with risk in obese men (BMI > 30, p-trend = 0.04), with a greater than 2-fold increased risk in the highest IGFmr quartile (OR 2.34, 95% CI 1.10–5.01). Risk was specifically increased for aggressive disease in obese men (OR 2.80, 95% CI 1.11–7.08). In summary, our large prospective study showed no overall association between the insulin-like growth factor axis and prostate cancer risk, however, IGFmr was related to risk for aggressive prostate cancer in obese men. © 2007 Wiley-Liss, Inc.

View Full Article (HTML) Get PDF (91K)